NO20085098L - Behandling av ischemisks sykdommer ved bruk av erytropoietin - Google Patents

Behandling av ischemisks sykdommer ved bruk av erytropoietin

Info

Publication number
NO20085098L
NO20085098L NO20085098A NO20085098A NO20085098L NO 20085098 L NO20085098 L NO 20085098L NO 20085098 A NO20085098 A NO 20085098A NO 20085098 A NO20085098 A NO 20085098A NO 20085098 L NO20085098 L NO 20085098L
Authority
NO
Norway
Prior art keywords
subject
erythropoietin
treatment
peripheral blood
ischemic diseases
Prior art date
Application number
NO20085098A
Other languages
English (en)
Inventor
Toshio Matsumoto
Tetsuya Kitagawa
Masahiro Abe
Masashi Akaike
Kazunari Nagayoshi
Kaname Yamamoto
Masato Higuchi
Original Assignee
Univ Tokushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokushima filed Critical Univ Tokushima
Publication of NO20085098L publication Critical patent/NO20085098L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En metode for regenerering av et blodkar, omfattende trinnene: (a) administrering av erytropoetin til individet; (b) oppsamling av perifert blod mononukleære celler fra individet; og (c) administrering av de oppsamlede perifert blod mononukleære celler til et målsted hos individet. Når erytropoetin blir administrert til et individ blir en perifert blod mononukleær celle (spesielt en CD34-positiv) rekruttert til det perifere blod til individet. Metoden er anvendelig for behandling av ischemiske sykdommer, så som perifer vaskulær lidelse.
NO20085098A 2006-06-07 2008-12-08 Behandling av ischemisks sykdommer ved bruk av erytropoietin NO20085098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006158998 2006-06-07
PCT/JP2007/061525 WO2007142288A1 (ja) 2006-06-07 2007-06-07 エリスロポエチンを用いた虚血性疾患の治療

Publications (1)

Publication Number Publication Date
NO20085098L true NO20085098L (no) 2009-02-27

Family

ID=38801534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085098A NO20085098L (no) 2006-06-07 2008-12-08 Behandling av ischemisks sykdommer ved bruk av erytropoietin

Country Status (17)

Country Link
US (1) US20090280094A1 (no)
EP (1) EP2047859A4 (no)
JP (2) JP5326079B2 (no)
KR (1) KR20090031547A (no)
CN (1) CN101460188B (no)
AR (1) AR061269A1 (no)
AU (1) AU2007255717B2 (no)
BR (1) BRPI0712063A2 (no)
CA (1) CA2654154A1 (no)
HK (1) HK1128419A1 (no)
IL (1) IL195648A0 (no)
MX (1) MX2008015392A (no)
NO (1) NO20085098L (no)
NZ (1) NZ573792A (no)
RU (1) RU2008152746A (no)
TW (1) TW200815026A (no)
WO (1) WO2007142288A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療
EP3150701B1 (en) 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations
CN101940594B (zh) * 2010-08-27 2013-12-04 上海士腾生物技术有限公司 用于治疗缺血性心血管疾病的制剂及其制备方法
CN101940590B (zh) * 2010-08-27 2013-09-18 上海士腾生物技术有限公司 促进创伤愈合的制剂及其制备方法
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
KR101544674B1 (ko) 2013-06-05 2015-09-02 서울대학교산학협력단 에리쓰로포이에틴으로 프라이밍된 혈관 생성능이 향상된 말초혈액 줄기세포 및 그 용도
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501010A (ja) 1984-12-04 1987-04-23 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド エリトロポエチンの生産方法
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
CN1764470A (zh) * 2003-03-27 2006-04-26 詹森药业有限公司 ***在中风康复中的用途
BRPI0408829A (pt) * 2003-03-27 2006-04-04 Janssen Pharmaceutica Nv uso de eritropoietina em recuperação de acidente vascular cerebral
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
JP2006158998A (ja) 2004-12-02 2006-06-22 Nippon Sheet Glass Co Ltd ロッドの反り選別装置
KR20170027868A (ko) * 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療

Also Published As

Publication number Publication date
EP2047859A1 (en) 2009-04-15
KR20090031547A (ko) 2009-03-26
CA2654154A1 (en) 2007-12-13
AR061269A1 (es) 2008-08-13
CN101460188B (zh) 2013-09-04
CN101460188A (zh) 2009-06-17
RU2008152746A (ru) 2010-07-20
IL195648A0 (en) 2011-08-01
JP2013116919A (ja) 2013-06-13
US20090280094A1 (en) 2009-11-12
AU2007255717A1 (en) 2007-12-13
BRPI0712063A2 (pt) 2011-12-20
TW200815026A (en) 2008-04-01
HK1128419A1 (en) 2009-10-30
JP5326079B2 (ja) 2013-10-30
EP2047859A4 (en) 2010-05-05
JPWO2007142288A1 (ja) 2009-10-29
AU2007255717B2 (en) 2013-07-11
NZ573792A (en) 2011-09-30
WO2007142288A1 (ja) 2007-12-13
MX2008015392A (es) 2009-05-05

Similar Documents

Publication Publication Date Title
NO20085098L (no) Behandling av ischemisks sykdommer ved bruk av erytropoietin
Gao et al. Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease
Tokuda et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease
Van Craenenbroeck et al. Effect of moderate aerobic exercise training on endothelial function and arterial stiffness in CKD stages 3-4: a randomized controlled trial
Di Lullo et al. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies
Johnson et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines
Ishii et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment–elevation myocardial infarction
Park et al. Effects of air pollution on heart rate variability: the VA normative aging study
NZ623454A (en) Pharmaceutical composition for the treatment of heart diseases
WO2012103025A3 (en) Methods for obtaining single cells and applications of single cell omics
CN107075473A (zh) 其中未分化细胞被去除的分化诱导的细胞群、其用途及其制备方法
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
Kiuchi et al. New approaches in the management of sudden cardiac death in patients with heart failure—targeting the sympathetic nervous system
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
El-Bassossy et al. Cardioprotection by 6-gingerol in diabetic rats
Ueno et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel
Grace et al. Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis
Cho et al. Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice:≥ 50% reduction from baseline versus< 70 mg/dL
Lee et al. Lack of modulatory effect of simvastatin on indoxyl sulfate-induced activation of cultured endothelial cells
Sbarouni et al. Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry-results from the Greek national cohort
Hayes et al. [LB. 02.06] APPARENT AND TRUE TREATMENT RESISTANT HYPERTENSION IN GP: A CROSS SECTIONAL STUDY OF PREVALENCE WITH CONSIDERATION OF MORBIDITY, WHITE COAT HYPERTENSION, DOSING AND ADHERENCE
RU2006136460A (ru) Способ индивидуального подбора иммунокоррегирующих препаратов для проведения иммунокоррегирующей терапии после трансплантации аутологичных стволовых клеток при лечении хронической сердечной недостаточности
RU2004136472A (ru) Способ лечения хронических диффузных заболеваний печени
Diaz-Ruiz et al. No. 37 Antidromic Median Palmar Sensory Latency: A New Test in Diagnosis of Carpal Tunnel Syndrome
Sinha et al. Telecardiology for chest pain management in Rural Bengal–A private venture model: A pilot project

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application